|
Studies | Patients (n) | Inclusion criteria/risk of CI-AKI | Mean age (years) | Males (%) | Baseline SCr (mg/dL) | Baseline eGFR (mL/min/1.73 m2) | Mean LVEF (%) | DM (%) | HF (%) | Treatment groups | Types of CM | CM dosage (mL) | Jadad score | No. of patients | Inclusion criteria/risk of CI-AKI | Mean age | Male (%) | Baseline SCr | Baseline eGFR | Mean LVEF | DM (%) | HF (%) | Groups | Types of CM | Dosage of CM | Jadad score |
|
Weisbord et al. [11] | 4993 | High risk for renal complications and scheduled for angiography | 69.8 | 93.6 | 132.6 | 50.2 | | 80.9 | 7.4 | SC vs. SB | Iodixanol or low-osmolar | 85 | 5 | 4993 | High risk for renal complications and scheduled for angiography | 69.8 | 93.6 | 132.6 | 50.2 | | 80.9 | 7.4 | SC vs. SB | Iodixanol or low-osmolar | 85 | 5 |
|
van Mourik et al. [24] | 74 | Symptomatic aortic valve stenosis and impaired renal function who underwent pre-TAVI CTA | 82.9 | 44.6 | 104.3 | 47.4 | | 31.1 | | SC vs. SB | Iopromide | 90 | 3 | 74 | Symptomatic aortic valve stenosis and impaired renal function who underwent pre-TAVI CTA | 82.9 | 44.6 | 104.3 | 47.4 | | 31.1 | | SC vs SB | Iopromide | 90 | 3 |
|
Saratzis et al. [25] | 58 | Elective EVAR for infrarenal AAA | 75 | 89.7 | | 65.5 | | 13.8 | | SC vs. SB | Iomeprol | 126 | 3 | 58 | Elective EVAR for infrarenal AAA | 75 | 89.7 | | 65.5 | | 13.8 | | SC vs SB | Iomeprol | 126 | 3 |
|
Maioli et al. [18] | 296 | Elective coronary angiographic procedures | 71 | 68.2 | 89.3 | | 48 | 24.7 | | SC vs. HDy | Iodixanol | 131 | 3 | 296 | Elective coronary angiographic procedures | 71 | 68.2 | 89.3 | | 48 | 24.7 | | SC vs HDy | Iodixanol | 131 | 3 |
|
Kooiman et al. [26] | 333 | CKD patients undergoing elective cardiovascular diagnostic or interventional contrast procedures | 73 | 64.6 | | 50.5 | | 38.7 | 16.5 | SC vs. SB | Not mentioned | 113 | 3 | 333 | CKD patients undergoing elective cardiovascular diagnostic or interventional contrast procedures | 73 | 64.6 | | 50.5 | | 38.7 | 16.5 | SC vs SB | Not mentioned | 113 | 3 |
|
Valette et al. [12] | 307 | Critically ill patients with stable renal function who received intravascular CM | 56.2 | 67.8 | 61.4 | | | 13.4 | 6.5 | SC vs. SB | Low-osmolar | 90 | 4 | 307 | Critically ill patients with stable renal function who received intravascular CM | 56.2 | 67.8 | 61.4 | | | 13.4 | 6.5 | SC vs SB | Low-osmolar | 90 | 4 |
|
Nijssen et al. [10] | 660 | High-risk patients with eGFR of 30–59 ml/min/1.73 m2, undergoing an elective procedure requiring CM administration | 72 | 61.7 | 118 | 47.4 | | 32.6 | | Non vs. SC | Iopromide | 90.5 | 3 | 660 | High-risk patients with eGFR of 30–59 ml/min/1.73 m2, undergoing an elective procedure requiring CM administration | 72 | 61.7 | 118 | 47.4 | | 32.6 | | Non vs SC | Iopromide | 90.5 | 3 |
|
Alonso et al. [27] | 93 | Patients receiving CM during CRT devices implantation | 66.5 | 65.3 | 110.5 | | 28.5 | 37 | | SC vs. SB | Iodixanol | 102 | 2 | 93 | Patients receiving CM during CRT devices implantation | 66.5 | 65.3 | 110.5 | | 28.5 | 37 | | SC vs SB | Iodixanol | 102 | 2 |
|
Usmiani et al. [28] | 124 | Coronary angiography/PCI with eGFR of less than 60 ml/min/1.73 m2 | 75 | 74 | 130.8 | 44 | 25 | 84 | | SC vs. RenalGuard | Iodixanol | 156 | 3 | 124 | Coronary angiography/PCI with eGFR of less than 60 ml/min/1.73 m2 | 75 | 74 | 130.8 | 44 | 25 | 84 | | SC vs RenalGuard | Iodixanol | 156 | 3 |
|
Turedi et al. [29] | 172 | Contrast-enhanced CTPA on suspicion of PE with at least one risk factor for CIN | 75.5 | 51.7 | 85.4 | | | | | SC vs. SB | Water-soluble, nonionic, low-osmolar | <100 | 3 | 172 | Contrast-enhanced CTPA on suspicion of PE with at least one risk factor for CIN | 75.5 | 51.7 | 85.4 | | | | | SC vs SB | Water-soluble, nonionic, low-osmolar | <100 | 3 |
|
Qian et al. [19] | 264 | CKD and CHF undergoing coronary procedures | 63.5 | 74.6 | 151 | 37.5 | 39.5 | 47.3 | | SC vs. HDy | Iodixanol | 166 | 5 | 264 | CKD and CHF undergoing coronary procedures | 63.5 | 74.6 | 151 | 37.5 | 39.5 | 47.3 | | SC vs HDy | Iodixanol | 166 | 5 |
|
Solomon et al. [30] | 391 | Elective coronary or peripheral angiography with eGFR <45 ml/min/1.73 m2 | 72 | 57.5 | 169.3 | 32.8 | | 59.1 | 35.5 | SC vs. SB | Not mentioned | 107 | 4 | 391 | Elective coronary or peripheral angiography with eGFR <45 ml/min/1.73 m2 | 72 | 57.5 | 169.3 | 32.8 | | 59.1 | 35.5 | SC vs SB | Not mentioned | 107 | 4 |
|
Martin-Moreno et al. [31] | 130 | Receiving CM for CT scan | 57.5 | 64.3 | 79.6 | | | | | Non vs SB | Not mentioned | 120 | 3 | 130 | Receiving CM for CT scan | 57.5 | 64.3 | 79.6 | | | | | Non vs SB | Not mentioned | 120 | 3 |
|
Jurado-Román et al. [32] | 408 | STEMI undergoing primary PCI | 63.1 | 73.4 | | 89 | | 22.5 | 14.7 | Non vs. SC | Iso-osmolar nonionic | 174 | 2 | 408 | STEMI undergoing primary PCI | 63.1 | 73.4 | | 89 | | 22.5 | 14.7 | Non vs SC | Iso-osmolar nonionic | 174 | 2 |
|
Barbanti et al. [13] | 112 | TAVR | 81 | 40.2 | 87.1 | 51.5 | 54.6 | 25 | | SC vs. RenalGuard | Buckinghamshire | 175 | 3 | 112 | TAVR | 81 | 40.2 | 87.1 | 51.5 | 54.6 | 25 | | SC vs RenalGuard | Buckinghamshire | 175 | 3 |
|
Yeganehkhah et al. [33] | 100 | CAG | 59.7 | 53 | 99.5 | | 43.8 | 39 | | SC vs. SB | Iohexol | 45.4 | 3 | 100 | CAG | 59.7 | 53 | 99.5 | | 43.8 | 39 | | SC vs SB | Iohexol | 45.4 | 3 |
|
Yang et al. [34] | 320 | Elective cardiovascular procedures including CAG or interventional treatment | 59.2 | 53.1 | 70.2 | 93.1 | 55.1 | 20 | | SC + NAC vs. SB + NAC | Iopromide | 125 | 3 | 320 | Elective cardiovascular procedures including CAG or interventional treatment | 59.2 | 53.1 | 70.2 | 93.1 | 55.1 | 20 | | SC + NAC vs SB + NAC | Iopromide | 125 | 3 |
|
Yang et al. [34] | 320 | Elective cardiovascular procedures including CAG or interventional treatment | 59.2 | 53.1 | 70.2 | 93.1 | 55.1 | 20 | | SC vs. SB | Iopromide | 125 | 3 | 320 | Elective cardiovascular procedures including CAG or interventional treatment | 59.2 | 53.1 | 70.2 | 93.1 | 55.1 | 20 | | SC vs SB | Iopromide | 125 | 3 |
|
Thayssen et al. [35] | 362 | STEMI undergoing primary PCI within 12 hours from the onset of chest pain | 62.5 | 78.5 | 77 | 90.5 | 50 | 9.7 | | SC vs. SB | Iodixanol | 140 | 5 | 362 | STEMI undergoing primary PCI within 12 hours from the onset of chest pain | 62.5 | 78.5 | 77 | 90.5 | 50 | 9.7 | | SC vs SB | Iodixanol | 140 | 5 |
|
Nieto-Rios et al. [36] | 220 | Tomography scan using CM or angiography | 60 | 57.7 | 115.8 | | | 37.3 | | SC vs. SB | Iohexol | 100 | 3 | 220 | Tomography scan using CM or angiography | 60 | 57.7 | 115.8 | | | 37.3 | | SC vs SB | Iohexol | 100 | 3 |
|
Manari et al. [37] | 592 | STEMI within 12 h from symptom onset referred for primary angioplasty | 65 | 74.8 | 88.5 | 81 | 48 | 16.6 | 11.8 | SC vs. SB | Iodixanol | 198 | 3 | 592 | STEMI within 12 h from symptom onset referred for primary angioplasty | 65 | 74.8 | 88.5 | 81 | 48 | 16.6 | 11.8 | SC vs SB | Iodixanol | 198 | 3 |
|
Mahmoodi et al. [38] | 350 | Coronary interventions | 64.48 | 51.4 | 103 | 64.8 | | | | SC vs. SB | Iohexol | | 2 | 350 | Coronary interventions | 64.48 | 51.4 | 103 | 64.8 | | | | SC vs SB | Iohexol | | 2 |
|
Luo et al. [39] | 216 | STEMI | 67 | 65.7 | 77 | 77.6 | | 25 | | Non vs. SC | Iopamiron | 234.9 | 3 | 216 | STEMI | 67 | 65.7 | 77 | 77.6 | | 25 | | Non vs SC | Iopamiron | 234.9 | 3 |
|
Kooiman et al. [40] | 548 | CKD patients receiving CE-CT | 72.1 | 60.4 | | 50.4 | | 26.8 | 16.4 | SC vs. SB | Iomeprol | 105 | 5 | 548 | CKD patients receiving CE-CT | 72.1 | 60.4 | | 50.4 | | 26.8 | 16.4 | SC vs SB | Iomeprol | 105 | 5 |
|
Kooiman et al. [41] | 138 | CKD patients receiving CTPA | 70.5 | 50 | | 49.2 | | 16.7 | 8 | Non vs. SB | Iopromide or iobitridol or iodixanol | 74 | 5 | 138 | CKD patients receiving CTPA | 70.5 | 50 | | 49.2 | | 16.7 | 8 | Non vs SB | Iopromide, or iobitridol, or iodixanol | 74 | 5 |
|
Brar et al. [17] | 396 | Referred to the cardiac catheterization laboratory with eGFR ≤ 60 mL/min/1.73 m2, and at least one of the following: DM, CHF, hypertension, or age older than 75 years | 72 | 61.9 | 123.8 | 48 | | 51.3 | 20.5 | SC vs. HDy | Ioxilan | 108 | 3 | 396 | Referred to the cardiac catheterization laboratory with eGFR ≤ 60 mL/min/1.73 m2, and at least one of the following: DM, CHF, hypertension, or age older than 75 years | 72 | 61.9 | 123.8 | 48 | | 51.3 | 20.5 | SC vs HDy | Ioxilan | 108 | 3 |
|
Akyuz et al. [42] | 225 | At least one of the high-risk factors for developing CI-AKI and undergoing CAG and/or PCI | 63.4 | 68.9 | 79.6 | 84.5 | 47.5 | 60.9 | 7.6 | Oral vs. SC | Not mentioned | 108 | 2 | 225 | At least one of the high-risk factors for developing CI-AKI and undergoing CAG and/or PCI | 63.4 | 68.9 | 79.6 | 84.5 | 47.5 | 60.9 | 7.6 | Oral vs SC | Not mentioned | 108 | 2 |
|
Kristeller et al. [43] | 92 | Stage 3 or higher CKD who underwent cardiac surgery using CPB | 72.5 | 57.6 | 119.1 | | | 44.6 | 34.8 | SC vs SB | Not mentioned | 79 | 5 | 92 | Stage 3 or higher CKD who underwent cardiac surgery using CPB | 72.5 | 57.6 | 119.1 | | | 44.6 | 34.8 | SC vs SB | Not mentioned | 79 | 5 |
|
Koc et al. [44] | 195 | DM patients | 62 | 52.3 | 88.4 | | | 100 | | SC vs. SB | Not mentioned | 90 | 4 | 195 | DM patients | 62 | 52.3 | 88.4 | | | 100 | | SC vs SB | Not mentioned | 90 | 4 |
|
Gu et al. [45] | 859 | Coronary angiography or angioplasty | 59 | 72.2 | 90.1 | 74.2 | | 20.6 | 0.6 | SC vs. SC + diuresis | Not mentioned | 100 | 2 | 859 | Coronary angiography or angioplasty | 59 | 72.2 | 90.1 | 74.2 | | 20.6 | 0.6 | SC vs SC + diuresis | Not mentioned | 100 | 2 |
|
Boucek et al. [46] | 120 | Diabetic patients with impaired renal function, undergoing intra-arterial or intravenous use of CM | 65 | 75 | 165 | 44.1 | | 100 | | SC vs. SB | Low-osmolar nonionic iodinated | 110 | 5 | 120 | Diabetic patients with impaired renal function, undergoing intra-arterial or intravenous use of CM | 65 | 75 | 165 | 44.1 | | 100 | | SC vs SB | Low-osmolar nonionic iodinated | 110 | 5 |
|
Marenzi et al. [47] | 170 | CKD undergoing coronary procedures | 73 | 78.2 | 154.7 | 39 | 51.5 | 36.4 | | SC vs. RenalGuard | Iomeprol | 170 | 3 | 170 | CKD undergoing coronary procedures | 73 | 78.2 | 154.7 | 39 | 51.5 | 36.4 | | SC vs RenalGuard | Iomeprol | 170 | 3 |
|
Kong et al. [48] | 80 | Definitive or suspected coronary artery disease | 56.5 | 53.8 | 105 | | | 23.8 | | Oral vs. SC | Iopromide | 152 | 3 | 80 | Definitive or suspected coronary artery disease | 56.5 | 53.8 | 105 | | | 23.8 | | Oral vs SC | Iopromide | 152 | 3 |
|
Klima et al. [49] | 258 | Renal insufficiency undergoing intravascular contrast procedures | 77 | 64 | 137 | 43.6 | | 37 | 44 | SC vs. SB | Not mentioned | 100 | 5 | 258 | Renal insufficiency undergoing intravascular contrast procedures | 77 | 64 | 137 | 43.6 | | 37 | 44 | SC vs SB | Not mentioned | 100 | 5 |
|
Gomes et al. [50] | 301 | Patients at moderate to high risk for developing CIN who were referred for elective CAG or PCI | 64 | 47.5 | 132.6 | | | 18.9 | | SC vs. SB | Not mentioned | 125 | 2 | 301 | Patients at moderate to high risk for developing CIN who were referred for elective CAG or PCI | 64 | 47.5 | 132.6 | | | 18.9 | | SC vs SB | Not mentioned | 125 | 2 |
|
Motohiro et al. [51] | 155 | eGFR <60 ml/min/1.73 m2 who were undergoing coronary angiography | 72.5 | 69.7 | 136.6 | 44.3 | 55 | 60 | | SC vs. SB | Iopamidol | 135 | 3 | 155 | eGFR <60 ml/min/1.73 m2 who were undergoing coronary angiography | 72.5 | 69.7 | 136.6 | 44.3 | 55 | 60 | | SC vs SB | Iopamidol | 135 | 3 |
|
Maioli et al. [52] | 300 | STEMI undergoing primary PCI | 65 | 25 | 95.9 | | 42.5 | 21.7 | 24 | Non vs. SB | Iodixanol | 216 | 3 | 300 | STEMI undergoing primary PCI | 65 | 25 | 95.9 | | 42.5 | 21.7 | 24 | Non vs SB | Iodixanol | 216 | 3 |
|
Lee et al. [53] | 382 | Diabetic patients with renal disease (serum creatinine >1.1 mg/dl and eGFR <60 ml/min/1.73 m2) | 68 | 70.9 | 132.6 | 46 | | 100 | | SC vs. SB | Iodixanol | 116.5 | 3 | 382 | Diabetic patients with renal disease (serum creatinine >1.1 mg/dl and eGFR <60 ml/min/1.73 m2) | 68 | 70.9 | 132.6 | 46 | | 100 | | SC vs SB | Iodixanol | 116.5 | 3 |
|
Hafiz et al. [54] | 320 | Patients with baseline renal insufficiency scheduled to undergo catheterization | 73 | 56.9 | 141.4 | | | 47.2 | | SC vs. SB | Nonionic, low-osmolar | 115 | 3 | 320 | Patients with baseline renal insufficiency scheduled to undergo catheterization | 73 | 56.9 | 141.4 | | | 47.2 | | SC vs SB | Nonionic, low-osmolar | 115 | 3 |
|
Briguori et al. [55] | 292 | High-risk patients with an eGFR ≤30 ml/min/1.73 m2 and/or a risk score ≥11 | 76 | 65.4 | 158.7 | 32 | 47 | 70.2 | 28.4 | SB vs. RenalGuard | Iodixanol | 140 | 3 | 292 | High-risk patients with an eGFR ≤30 ml/min/1.73 m2 and/or a risk score ≥11 | 76 | 65.4 | 158.7 | 32 | 47 | 70.2 | 28.4 | SB vs RenalGuard | Iodixanol | 140 | 3 |
|
Wróbel et al. [56] | 102 | Coronary angiography and/or angioplasty, and had comorbidities that increase the risk of CIN | 65.5 | 56.9 | 236.4 | | | | | Oral vs. SC | Loversol | 69.5 | 2 | 102 | Coronary angiography and/or angioplasty, and had comorbidities that increase the risk of CIN | 65.5 | 56.9 | 236.4 | | | | | Oral vs SC | Loversol | 69.5 | 2 |
|
Vasheghani-Farahani et al. [57] | 72 | CAG, with SCr 1.5 mg/dL within 2 weeks, having at least 1 of the risk factors | 62 | 79.2 | 151.2 | 44.2 | 36.1 | 34.7 | 45.8 | 0.45 SC vs. SB | Iohexol | 117.5 | 3 | 72 | CAG, with SCr 1.5 mg/dL within 2 weeks, having at least 1 of the risk factors | 62 | 79.2 | 151.2 | 44.2 | 36.1 | 34.7 | 45.8 | 0.45 SC vs SB | Iohexol | 117.5 | 3 |
|
Cho et al. [58] | 91 | Undergoing an elective CAG | 78 | 50.5 | 123 | | | 38.5 | 17.6 | SC vs. SB | Isoversol | 128 | 2 | 91 | Undergoing an elective CAG | 78 | 50.5 | 123 | | | 38.5 | 17.6 | SC vs SB | Isoversol | 128 | 2 |
|
Vasheghani-Farahani et al. [59] | 265 | Serum creatinine level of 1.5 mg/dL or greater undergoing elective CAG | 63.3 | 83 | 145.4 | 45.9 | 51.7 | 21.5 | | SC vs. SB | Iohexol | 114 | 5 | 265 | Serum creatinine level of 1.5 mg/dL or greater undergoing elective CAG | 63.3 | 83 | 145.4 | 45.9 | 51.7 | 21.5 | | SC vs SB | Iohexol | 114 | 5 |
|
Tamura et al. [60] | 144 | Scheduled for elective CAG or PCI | 72.8 | 87.5 | 121.1 | 39.1 | 57.8 | 58.3 | | SC vs. SB | Iohexol | 85 | 3 | 144 | Scheduled for elective CAG or PCI | 72.8 | 87.5 | 121.1 | 39.1 | 57.8 | 58.3 | | SC vs SB | Iohexol | 85 | 3 |
|
Pakfetrat et al. [61] | 192 | Undergoing elective CAG or PCI | 57.9 | 61.5 | 97.2 | 72.2 | 50.5 | 29.7 | 5.2 | SC vs. SB | Iodixanol | 65 | 4 | 192 | Undergoing elective CAG or PCI | 57.9 | 61.5 | 97.2 | 72.2 | 50.5 | 29.7 | 5.2 | SC vs SB | Iodixanol | 65 | 4 |
|
Haase et al. [62] | 100 | At increased risk of postoperative acute renal dysfunction who were scheduled for elective or urgent cardiac surgery necessitating the use of CPB | 71 | 66 | 90.7 | | | | | SC vs. SB | Not mentioned | | 5 | 100 | At increased risk of postoperative acute renal dysfunction who were scheduled for elective or urgent cardiac surgery necessitating the use of CPB | 71 | 66 | 90.7 | | | | | SC vs SB | Not mentioned | | 5 |
|
Budhiraja et al. [63] | 187 | Nonemergent CAG, baseline serum creatinine >1.0 mg/dL, and availability of serum creatinine values at days 1–3 | 68 | | 125.8 | 57.2 | | 30.5 | | SC vs. SB | Iopromide | 199 | 2 | 187 | Nonemergent CAG, baseline serum creatinine >1.0 mg/dL, and availability of serum creatinine values at days 1–3 | 68 | | 125.8 | 57.2 | | 30.5 | | SC vs SB | Iopromide | 199 | 2 |
|
Angoulvant et al. [64] | 201 | Scheduled for elective CAG, with or without PTCA with a baseline SCr < 140 μmol/L | 62 | 80.6 | 86.2 | | | | | Oral vs. SC | Not mentioned | 290 | 3 | 201 | Scheduled for elective CAG, with or without PTCA with a baseline SCr< 140 μmol/L | 62 | 80.6 | 86.2 | | | | | Oral vs SC | Not mentioned | 290 | 3 |
|
Maioli et al. [65] | 502 | Undergoing coronary angiographic procedures with estimated creatinine clearance <60 ml/min | 74 | 59 | 107 | | 46.5 | 59.1 | | SC vs. SB | Iodixanol | 165 | 3 | 502 | Undergoing coronary angiographic procedures with estimated creatinine clearance <60 ml/min | 74 | 59 | 107 | | 46.5 | 59.1 | | SC vs SB | Iodixanol | 165 | 3 |
|
Chen et al. [66] | 660 | Myocardial ischemia (angina or positive exercise treadmill) scheduled for PCI, with SCr<1.5 mg/dl | 60 | 85 | 114.9 | | 54 | 8 | | Non vs. SC | Iso-osmolar nonionic | 285 | 2 | 660 | Myocardial ischemia (angina or positive exercise treadmill) scheduled for PCI, with SCr < 1.5 mg/dl | 60 | 85 | 114.9 | | 54 | 8 | | Non vs SC | Iso-osmolar nonionic | 285 | 2 |
|
Chen et al. [66] | 276 | Myocardial ischemia (angina or positive exercise treadmill) scheduled for PCI, with SCr ≥ 1.5 mg/dl | 63 | 82 | 221 | | 41 | 22 | | Non vs. SC | Iso-osmolar nonionic | 298 | 2 | 276 | Myocardial ischemia (angina or positive exercise treadmill) scheduled for PCI, with SCr ≥ 1.5 mg/dl | 63 | 82 | 221 | | 41 | 22 | | Non vs SC | Iso-osmolar nonionic | 298 | 2 |
|
Brar et al. [67] | 353 | Patients with stable renal disease and undergoing CAG | 71 | 63.9 | 131.7 | 48 | 57 | 44.5 | 27.2 | SC vs. SB | Ioxilan | 132 | 5 | 353 | Patients with stable renal disease and undergoing CAG | 71 | 63.9 | 131.7 | 48 | 57 | 44.5 | 27.2 | SC vs SB | Ioxilan | 132 | 5 |
|
Adolph et al. [68] | 145 | Stable renal insufficiency and undergoing elective diagnostic or interventional coronary angiography | 72.6 | 77.9 | 132.6 | | | 33.8 | | SC vs. SB | Iodixanol | 140 | 5 | 145 | Stable renal insufficiency and undergoing elective diagnostic or interventional coronary angiography | 72.6 | 77.9 | 132.6 | | | 33.8 | | SC vs SB | Iodixanol | 140 | 5 |
|
Schmidt et al. [69] | 96 | CAG | 67.6 | 74 | 146.7 | | | 64.6 | | SC vs. SB | Optiray | 186 | 2 | 96 | CAG | 67.6 | 74 | 146.7 | | | 64.6 | | SC vs SB | Optiray | 186 | 2 |
|
Ozcan et al. [70] | 264 | Scheduled for CAG or PCI and had a baseline creatinine level >1.2 mg/dL | 69 | 74.6 | 122.9 | | | 45.1 | 26.5 | SC vs. SB | Ioxaglate | 110 | 2 | 264 | Scheduled for CAG or PCI and had a baseline creatinine level >1.2 mg/dL | 69 | 74.6 | 122.9 | | | 45.1 | 26.5 | SC vs SB | Ioxaglate | 110 | 2 |
|
Masuda et al. [71] | 59 | Scheduled to undergo an emergency coronary angiography or intervention | 75 | 44.1 | 116.2 | | | 30.5 | | SC vs. SB | Iopamidol | 116 | 3 | 59 | Scheduled to undergo an emergency coronary angiography or intervention | 75 | 44.1 | 116.2 | | | 30.5 | | SC vs SB | Iopamidol | 116 | 3 |
|
Dussol et al. [72] | 156 | CKD, who were undergoing radiological procedures with CM | 65 | 67.9 | 204.5 | 33.1 | | 28.8 | 16 | SC vs. SC + diuresis | Nonionic, low osmolar | 117 | 5 | 156 | CKD, who were undergoing radiological procedures with CM | 65 | 67.9 | 204.5 | 33.1 | | 28.8 | 16 | SC vs SC + diuresis | Nonionic, low osmolar | 117 | 5 |
|
Mueller et al. [73] | 425 | Scheduled for elective or emergency PCI | 64 | 75 | | 89 | | 16 | | 0.45 SC vs. SC | Iopromide | 226 | 2 | 425 | Scheduled for elective or emergency PCI | 64 | 75 | | 89 | | 16 | | 0.45 SC vs SC | Iopromide | 226 | 2 |
|
Merten et al. [74] | 119 | Stable renal insufficiency undergoing diagnostic or interventional procedures requiring radiographic contrast, SCr> 1.1 mg/dL | 68 | 74.8 | 159.1 | | | 47.9 | | SC vs. SB | Iopamidol | 132 | 3 | 119 | Stable renal insufficiency undergoing diagnostic or interventional procedures requiring radiographic contrast, SCr> 1.1 mg/dL | 68 | 74.8 | 159.1 | | | 47.9 | | SC vs SB | Iopamidol | 132 | 3 |
|
Trivedi et al. [75] | 53 | Scheduled to undergo nonemergency CAG | 67.9 | 98.1 | 106.4 | | 52.1 | 18.9 | | Oral vs. SC | Ionic, low-osmolar | 148 | 2 | 53 | Scheduled to undergo nonemergency CAG | 67.9 | 98.1 | 106.4 | | 52.1 | 18.9 | | Oral vs SC | Ionic, low-osmolar | 148 | 2 |
|
Mueller et al. [76] | 1383 | Scheduled for elective or emergency CAG | 64 | 74.4 | 81.77 | | | 15.7 | | 0.45 SC vs. SC | Ultravist or imeron | 234 | 2 | 1383 | Scheduled for elective or emergency CAG | 64 | 74.4 | 81.77 | | | 15.7 | | 0.45 SC vs SC | Ultravist, or imeron | 234 | 2 |
|